What is BlueSemi?
BlueSemi operates at the intersection of semiconductor engineering and digital health, focusing on the creation of non-invasive diagnostic tools. The company specializes in the analysis of six key physiological vitals, leveraging sophisticated sensor arrays to provide real-time health insights. By integrating these capabilities into wearable and portable form factors, BlueSemi addresses the growing demand for continuous, remote patient monitoring and preventative healthcare solutions. Its market position is defined by its ability to bridge the gap between complex clinical diagnostics and consumer-accessible technology, a feat made possible through strategic partnerships with global hardware and software giants.
How much funding has BlueSemi raised?
BlueSemi has raised a total of $69.3M across 2 funding rounds:
Angel/Seed
$300K
Debt
$69M
Angel/Seed (2020): $300K with participation from Google, KLA, Microsoft, and Samsung Electronics
Debt (2021): $69M led by Global Emerging Markets
Key Investors in BlueSemi
Global Emerging Markets
Global Emerging Markets is a $3.4 billion alternative investment group that manages a diverse array of investment vehicles, specializing in private investments in public equities and venture capital across emerging markets.
Google is a global technology leader focused on organizing the world's information, with a significant interest in digital health, cloud computing, and artificial intelligence applications.
KLA
KLA Corporation is a premier semiconductor equipment manufacturer that develops advanced process control and metrology systems essential for high-precision chip fabrication.
What's next for BlueSemi?
With the recent infusion of capital, BlueSemi is poised to accelerate its product roadmap and expand its global footprint. The strategic focus will likely shift toward optimizing manufacturing processes for its sensor technology and deepening its integration with existing digital health ecosystems. As the company moves into this enterprise-level phase, the emphasis will be on scaling production to meet international demand while maintaining the high precision required for medical-grade diagnostics. Future growth will likely involve expanding the scope of its vitals analysis and pursuing regulatory certifications to facilitate broader adoption in clinical and home-care settings, ensuring that its non-invasive solutions become a standard component of the modern health-tech stack.
See full BlueSemi company page
